Pharmacoinvasive approach for stemi

54
Pharmaco-Invasive approach in patients of STEMI (ST Elevation Myocardial Infarction)

Transcript of Pharmacoinvasive approach for stemi

Page 1: Pharmacoinvasive approach for stemi

Pharmaco-Invasive approach in patients of STEMI (ST Elevation Myocardial Infarction)

Page 2: Pharmacoinvasive approach for stemi
Page 3: Pharmacoinvasive approach for stemi
Page 4: Pharmacoinvasive approach for stemi
Page 5: Pharmacoinvasive approach for stemi
Page 6: Pharmacoinvasive approach for stemi
Page 7: Pharmacoinvasive approach for stemi
Page 8: Pharmacoinvasive approach for stemi
Page 9: Pharmacoinvasive approach for stemi
Page 10: Pharmacoinvasive approach for stemi
Page 11: Pharmacoinvasive approach for stemi
Page 12: Pharmacoinvasive approach for stemi
Page 13: Pharmacoinvasive approach for stemi
Page 14: Pharmacoinvasive approach for stemi
Page 15: Pharmacoinvasive approach for stemi
Page 16: Pharmacoinvasive approach for stemi
Page 17: Pharmacoinvasive approach for stemi
Page 18: Pharmacoinvasive approach for stemi
Page 19: Pharmacoinvasive approach for stemi
Page 20: Pharmacoinvasive approach for stemi
Page 21: Pharmacoinvasive approach for stemi

Primary Endpoint30-day death, re-MI, HF, severe recurrent ischemia,

cardiogenic shock

Page 22: Pharmacoinvasive approach for stemi
Page 23: Pharmacoinvasive approach for stemi
Page 24: Pharmacoinvasive approach for stemi
Page 25: Pharmacoinvasive approach for stemi
Page 26: Pharmacoinvasive approach for stemi
Page 27: Pharmacoinvasive approach for stemi

Study Protocol

Page 28: Pharmacoinvasive approach for stemi

TIMI Flow rates

Page 29: Pharmacoinvasive approach for stemi

Single endpoints upto 30 days

Page 30: Pharmacoinvasive approach for stemi

STROKE RATES

Page 31: Pharmacoinvasive approach for stemi

In Hospital bleeding complications

Page 32: Pharmacoinvasive approach for stemi
Page 33: Pharmacoinvasive approach for stemi
Page 34: Pharmacoinvasive approach for stemi

Indian Scenario

Page 35: Pharmacoinvasive approach for stemi

• In India, the prevalence of STEMI is rising exponentially leading

to CV morbidity and mortality. Despite advancement in

reperfusion therapy(pharmacological and interventional),the

overall utilization, system of care and timely reperfusion remains

suboptimal.

Page 36: Pharmacoinvasive approach for stemi

Challenges for STEMI system of care in India• Primary PCI is available to <10% STEMI patients in India.

• 1.Lack of awareness• 2.Lack of transfer facilities. Unavailability of hospital with PCI facility.• 3.Casualty/ED –to cath lab Finance problem Obtaining consent Cath lab occupied Unavailability of cardiologist round the clock.

Page 37: Pharmacoinvasive approach for stemi

• Patient awareness and education for early symptom

identification.

• Education required for General Practitioners /Physicians to

implement early time dependent STEMI management.

• PCI is the GOLD standard, yet remains unaccessible to majority

of patients.

Page 38: Pharmacoinvasive approach for stemi

Plight of Reperfusion:What happens in real world ?

• Most complete data about contemporary trends in STEMI

patients in India comes from CREATE Registry, Kerala ACS

Registry.

• CREATE registry, large of its kind on ACS patients from 89

large hospital centers from 10 regions and 50 cities across

India.

• Kerala Registry 25,748 consecutive ACS patients from 2007

-2009 in 125 hospitals in Kerala.

Page 39: Pharmacoinvasive approach for stemi

CREATE Registry

CREATE Developed countries

Number of pts enrolled 20,468

% of STEMI 60% (12,405) 40%

Median time for arrival to hospital after symptom onset

300 min 140 -170 min

For intiation of fibrinolysis 50 min 32-40 min

Using ambulance 5%

Fibrinolytic therapy 59%

Primary PCI 9%

Page 40: Pharmacoinvasive approach for stemi
Page 41: Pharmacoinvasive approach for stemi

Kerala Registry

• STEMI was the most common ACS admission.

• Highest in hospital mortality rates and non fatal events.

• Less likely to have any formal education.

• Present more than 6 hrs after symptom onset.

• 90% received antiplatelets therapy,

• Thrombolytics were used in 41% of STEMI pts.

• Inappropriate thrombolysis was relatively high.

Page 42: Pharmacoinvasive approach for stemi

What is Pharmaco –Invasive approach

• It means FIRST administering EARLY fibrinolysis and then

SYSTEMATICALLY performing an angiography (and then PCI

if needed) WITHIN 3-24 hrs AFTER the START of fibrinolytic

therapy,REGARDLESS of whether fibrinolysis RESULTS in

SUCCESSFUL REPERFUSION or not.

• In the event of fibrinolytic failure, a Rescue PCI should be

immediately performed where one need not wait for the initial 3

hour window.

Page 43: Pharmacoinvasive approach for stemi

Why it has to be stressed much regarding this approach ?

• Time is Myocardium.

• For each 30 min delay in treatment in STEMI patient,1 yr mortality

increases by 7.5%.

• Mortality benefit with primary PCI is lost if PCI related delay

exceeded 60 min. Nallamothu et al ,Am J Cardiol,2004;94:772-774

• Practically, early fibrinolytic therapy can compensate for PCI

related delay.

• Proportional mortality reduction was significantly higher in patients

treated within 2 hrs with fibrinolytics..

Circulation 2004;109:1223-1225

Page 44: Pharmacoinvasive approach for stemi

Indications• It is appropriate for patients with STEMI who are eligible for

treatment with fibrinolytics drugs and in whom Transfer time ≥30 min, or DTB(door to balloon) time≥90 min, [FMC to balloon time > 120 min].

• PCI related delay : (door to balloon) – (door to needle) > 60

minutes.

Shortening the time to reperfusion of the Infarct related artery.

Optimal reperfusion strategy for patients with STEMI.

Page 45: Pharmacoinvasive approach for stemi

2013 Consensus Statement for Early Reperfusion and Pharmaco-Invasive approach

in patients presenting with Chest pain Diagnosed as STEMI (ST Elevation

Myocardial Infarction) in an Indian Setting

Developed in collaboration with STEMI India

JJ Dalal,T Alexander,V.Dayasagar et al.

ORIGINAL ARTICLE

JAPI.Vol 62.June 2014.

Page 46: Pharmacoinvasive approach for stemi

Early Reperfusion and Pharmaco Invasive approach

1.FMC at the level of General practitioner or consulting physician in private clinic/OPD.

All patients of chest pain/suspected of AMI on clinical diagnosis should

receive prophylactic dose of 350 mg soluble/chewable aspirin

immediately (not enteric coated).

ECG for diagnosis.

Clopidogrel (300mg <75 yrs, 75 mg if >75 yrs) and atorvastatin (40-80

mg) after confirmation by ECG.

Transfer immediately by ambulance to nearest PCI capable

hospital/hospitals where fibrinolysis is possible.

Page 47: Pharmacoinvasive approach for stemi

• Avoid referring patients to diagnostic centers as they take 3-4 hrs of precious time for ECG reporting that may add to delay in timely interventions.

• Condition of the patient to be explained to attendants and gain their confidence for preparedness for PCI

Page 48: Pharmacoinvasive approach for stemi

2.First/Second Medical contact at the level of emergency

physician at non PCI capable hopsital/nursing home capable of

fibrinolysis.

• Transfer to PPCI capable center only if transfer time < 30 min.

• Call the PPCI capable hospital and send the case.

• If occupied –thrombolyse and then transfer.

• If > 30 min - thrombolyse immediately.

Page 49: Pharmacoinvasive approach for stemi

3.Medical contact at the level of PPCI capable hospitals

• Patient counselling

• ED- cath lab transfer

• Patient relative unwilling for quick decision.

• Cath lab occupied.

• DTB <90 min – PPCI

• DTB > 90min - fibrinolysis

Page 50: Pharmacoinvasive approach for stemi

Choice of agents

• Tenecteplase 0.53 mg/kg single blous iv over 5 seconds (LOE 1 A)• Reteplase 10 MU bolus – 30 mins +10 MU bolus (LOE grade 1B)• Alteplase 15 mg IV bolus,0.75 mg/kg over 30 min ,0.5 mg/kg

over 60 min (LOE grade 1C)• Streptokinase 1.5 MU over 30 -60 min (LOE grade 2B)

• For streptokinase –perform PCI in the later half of 3-24 hrs.• Radial approach is the preferred route.

Page 51: Pharmacoinvasive approach for stemi

Choice of fibrinolyticsFIRST GENERATION SECOND THIRD IN PIPELINE

Streptokinase Alteplase Increased fibrin specificity

Lanoteplase

antigenic accelerated dose Resistance to plasminogen activators

Alfimeprase

IV infusion IV infusion Reteplase 60%

less fibrin specific 54% Tenecteplase

TIMI grade 3flow more specific

32% single bolus

wt based regimen

TIMI 3 flow - 63%

Page 52: Pharmacoinvasive approach for stemi
Page 53: Pharmacoinvasive approach for stemi

PCI

FMC to PCI capable hospital

Primary PCI

<90 min

Facilitated PCI(use of half dose

of fibrinolyti

cs)

obsolete

Deferred PCI

Stenting later

Pharmaco Invasive approach >90 min

PCI 3-24 hrs after

fibrinolysis

PCI 14-24 hrs

after STK

Delayed PCI 12-72 hrs

after STEMI

FMC to Non PCI hosptial

Transport <120 min

(including 90 min)

Primary PCI

> 120 min

PI approach

PCI

Failed thrombolysis

Rescue PCI

Page 54: Pharmacoinvasive approach for stemi

Thank you